AbbVie Price Target Raised by Guggenheim Ahead of Q1 Earnings
Guggenheim has recently increased its price target for AbbVie (NYSE: ABBV) from $242 to $249, while maintaining a Buy rating. This adjustment comes as the pharmaceutical giant prepares for its first-quarter earnings release on April 29, 2026. The firm’s decision reflects a recalibration of its financial model based on updated prescription data and insights gained from discussions with AbbVie’s investor relations team.
Financial Projections and Earnings Estimates
For the first quarter of 2026, Guggenheim forecasts AbbVie’s revenue to reach approximately $14.65 billion, with earnings per share (EPS) projected at $2.57. These figures are slightly lower than consensus estimates, which predict revenues of $14.72 billion and EPS of $2.92. The discrepancy in EPS is primarily due to the market not fully incorporating a previously announced dilution of $0.41 related to an in-process R&D charge. This adjustment has led to a revised guidance range of $2.56 to $2.60.
Revised Medium-Term Outlook
In addition to short-term projections, Guggenheim has adjusted its medium-term outlook for AbbVie. The firm has raised growth expectations for its immunology portfolio, particularly for drugs like Skyrizi and Rinvoq. These medications have shown promising results in clinical studies and are expected to drive significant revenue growth. Conversely, projections for the aesthetics segment, which includes products like Botox and Juvederm, have been trimmed based on recent market trends, indicating a potential slowdown in this area.
Long-Term Growth Prospects
These revisions to both short-term and medium-term estimates have allowed Guggenheim to raise its sales and earnings expectations for the period between 2028 and 2032. The firm is optimistic that AbbVie can achieve high single-digit revenue growth throughout the remainder of the decade. This confidence stems from AbbVie’s robust existing portfolio, alongside potential pipeline developments and business opportunities that could arise as the company continues to innovate.
Market Performance and Investor Sentiment
Despite experiencing an approximate 8% decline in its shares year-to-date, AbbVie’s performance has been relatively stable compared to the modest decline seen in the S&P 500 index. This resilience has led Guggenheim to maintain a positive outlook for AbbVie, emphasizing that the company’s strong fundamentals and pipeline capabilities should support its growth trajectory in the coming years.
Conclusion
As AbbVie approaches its earnings release, investors will be keenly watching its performance against these revised expectations. With a strong portfolio in immunology and an ongoing focus on innovation, AbbVie remains a key player in the pharmaceutical sector, and Guggenheim’s increased price target reflects a bullish sentiment on its future potential.
